2 weeks Ago By ABMN Staff
Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ) – Leerink Partnrs issued their FY2027 EPS estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M.
Foroohar expects that the company will post earnings per share of ($0.84) for the year. The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.
57) per share. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report ) last issued its earnings results on Friday, February 28th. The company reported ($0.
53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17).
Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%.
The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million.
During the same period in the prior year, the business posted ($0.42) EPS. The company’s revenue for the quarter was down 57.
8% compared to the same quarter last year. Check Out Our Latest Stock Analysis on RXRX Recursion Pharmaceuticals Stock Performance NASDAQ:RXRX opened at $5.50 on Friday.
The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.
04. The firm has a market capitalization of $2.21 billion, a PE ratio of -3.
59 and a beta of 1.00. Recursion Pharmaceuticals has a twelve month low of $3.
79 and a twelve month high of $12.36. The stock’s 50-day simple moving average is $6.
62 and its 200 day simple moving average is $6.79. Institutional Trading of Recursion Pharmaceuticals Institutional investors have recently modified their holdings of the business.
Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth about $26,000. Private Trust Co.
NA acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $27,000. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter.
GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its position in Recursion Pharmaceuticals by 21.1% during the 4th quarter.
Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in Recursion Pharmaceuticals by 43.7% during the 4th quarter.
NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after purchasing an additional 2,387 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile ( Get Free Report ) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Featured Articles Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
